Overcoming Multidrug Resistance in Cancer: Clinical Studies of P-Glycoprotein Inhibitors

  • Helen M. ColeyEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 596)


Chemotherapy remains the mainstay in the treatment and management of many cancers. However, this treatment modality is fraught with difficulties associated with toxicity and also the emergence of chemotherapy resistance is a considerable problem. Cancer scientists and oncologists have worked together for some time to find ways of understanding anticancer drug resistance and also to develop pharmacological strategies to overcome that resistance. The greatest focus has been on the reversal of the multidrug resistance (MDR) phenotype by inhibition of the ATP-binding cassette (ABC) drug transporters. Inhibitors of ABC transporters – termed MDR modulators – have in the past been numerous and have occupied industry and academia in drug discovery programs. The field has been fraught with difficulties and disappointments but, nonetheless, we are currently considering the fourth generation of MDR modulator development with much data pending from the clinical trials with the third-generation modulators. First-generation MDR modulator compounds were very diverse and broad spectrum pharmacological agents which fuelled the excitement surrounding the research into the MDR phenotype in cancer at the time. Second-generation agents were very heavily evaluated in mechanistic studies and formed the basis for a number of oncology portfolios of big pharmaceutical companies. Given this input, a number of clinical trials were carried out, the results of which were somewhat disappointing. Even with the modest evidence of active combinations, trial data were considered promising enough to warrant development of the third-generation of modulators. A number of key molecules have been identified with potent, long lasting MDR reversal properties, and minimal pharmacokinetic interaction with the co-administered cytotoxic agent. The results from a number of these trials are eagerly awaited and there are many in the cancer research community who remain committed to this area of anticancer drug discovery.

Key words:

MDR modulator, ABC transporters, P-glycoprotein, Pharmacokinetic interaction 


  1. 1.
    Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162CrossRefPubMedGoogle Scholar
  2. 2.
    Plumb JA, Strathdee G, Sludden J, Kaye SB (2000) Reversal of drug resistance in human tumour xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH gene promoter. Cancer Res 60:6039–6044PubMedGoogle Scholar
  3. 3.
    Marathi UK, Dolan ME (1994) Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin and 1, 3-bis(2-chlroethy)-1-nitrosourea in vitro and in vivo. Biochem Pharmacol 48:2127–2134CrossRefPubMedGoogle Scholar
  4. 4.
    Scotto KW (2002) Transcriptional regulation of ABC transporters. Oncogene 22:7496–7511CrossRefGoogle Scholar
  5. 5.
    Agrawal M, Abraham J, Balis FM et al (2003) Increased 99mTc-sestamibi accumulation in normal liver and drug resistant tumours after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res 9:650–656PubMedGoogle Scholar
  6. 6.
    Linn SC, Pinedo HM, van Ark-Otte J (1997) Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71:787–795CrossRefPubMedGoogle Scholar
  7. 7.
    Rudas M, Filipits M, Taucher S (2003) Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Treat 81: 149–157CrossRefGoogle Scholar
  8. 8.
    Mechetner E, Kyshtoobayeva A, Zonis S (1998) Levels of multidrug resistance (MDR1) P-glycoprotein expression in human breast cancer correlate with in vitro resistance to Taxol and doxorubicin. Clin Cancer Res 4:389–398PubMedGoogle Scholar
  9. 9.
    Abolhoda A, Wilsin AE, Ross H et al (1999) Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 5: 3352–3356PubMedGoogle Scholar
  10. 10.
    Krishna R, Mayer LD (2000) Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11:265–283CrossRefPubMedGoogle Scholar
  11. 11.
    Ferry DR, Trauneker H, Kerr DJ (1996) Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A:1070–1081CrossRefPubMedGoogle Scholar
  12. 12.
    Ambudkar SV, Dey S, Hrycyna CA et al (1999) Biochemical, cellular and pharmacological aspects of the multidrug transporter. Ann Rev Pharmacol Toxicol 39:361–398CrossRefGoogle Scholar
  13. 13.
    Benson AB, Trump DL, Koeller JM et al (1985) Phase I Study of vinblastine and verapamil given by concurrent i.v. infusion. Cancer Treat Rep 69:795–799PubMedGoogle Scholar
  14. 14.
    Coley HM, Twentyman PR, Workman P (1989) Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporine A. Biochem Pharmacol 38: 4467–4475CrossRefPubMedGoogle Scholar
  15. 15.
    Silbermann MH, Boersma AW, Janssen AL et al (1989) Effects of cyclosporin A and verapamil on the intracellular daunorubicin accumulation in Chinese hamster ovary cells with increasing levels of drug-resistance. Int J Cancer 44:722–726CrossRefPubMedGoogle Scholar
  16. 16.
    Tamai I, Safa AR (1990) Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J Biol Chem 265: 16509–16513PubMedGoogle Scholar
  17. 17.
    Tamai I, Safa AR (1991) Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 266: 16796–16800PubMedGoogle Scholar
  18. 18.
    Goldberg H, Ling V, Wong PY, Skorecki K (1998) Reduced cyclosporin accumulation in multidrug-resistant cells. Biochem Biophys Res Commun 152:552–558CrossRefGoogle Scholar
  19. 19.
    Chan HS, Thorner PS, Haddad G (1990) Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689–704PubMedGoogle Scholar
  20. 20.
    Chan HS, Haddad G, Thorner PS (1991) P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608–1614CrossRefPubMedGoogle Scholar
  21. 21.
    Chan HS, DeBoer G, Thiessen JJ (1996) Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res 2: 1499–1508PubMedGoogle Scholar
  22. 22.
    Lum BL, Kaubisch S, Yahanda AM et al (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635–1642PubMedGoogle Scholar
  23. 23.
    Yahanda AM, Alder KM, Fisher GA et al (1992) Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10:1624–1634PubMedGoogle Scholar
  24. 24.
    Callaghan R, Higgins CF (1995) Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br J Cancer 71:294PubMedGoogle Scholar
  25. 25.
    Fine RL, Sachs CW, Albers M (1991) Tamoxifen potentiates the cytotoxicity of vinblastine by increasing intracellular drug accumulation. Proc Am Assoc Cancer Res 32:375Google Scholar
  26. 26.
    Ramu A, Glaubiger D, Fuks Z (1984) Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res 44: 4392–4395PubMedGoogle Scholar
  27. 27.
    Stuart NS, Philip P, Harris AL et al (1992) High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br J Cancer 66:833–839PubMedGoogle Scholar
  28. 28.
    Damiani D, Michieli M, Michelutti A et al (1993) P170-associated resistance to doxorubicin, daunorubicin and idarubicin. Anticancer Drugs 4:173–180CrossRefPubMedGoogle Scholar
  29. 29.
    Haussermann K, Benz B, Gekeler V, Schumacher K, Eichelbaum M (1991) Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines. Eur J Clin Pharmacol 40:53–59CrossRefPubMedGoogle Scholar
  30. 30.
    Motzer RJ, Lyn P, Fischer P et al (1995) Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 13:1958–1965PubMedGoogle Scholar
  31. 31.
    Warner E, Hedley D, Andrulis I et al (1998) Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res 4:1451–1457PubMedGoogle Scholar
  32. 32.
    Gaveriaux C, Boesch D, Boelsterli JJ et al (1989) Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives. Br J Cancer 60:867–871PubMedGoogle Scholar
  33. 33.
    Jachez B, Nordmann R, Loor F (1993) Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J Natl Cancer Inst 85:478–483CrossRefPubMedGoogle Scholar
  34. 34.
    Keller RP, Altermatt HJ, Nooter K et al (1992) SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 50:593–597CrossRefPubMedGoogle Scholar
  35. 35.
    Pourtier-Manzanedo A, Didier AD, Muller CD, Loor F (1992) SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells. Anticancer Drugs 3:419–425CrossRefPubMedGoogle Scholar
  36. 36.
    Te Boekhorst PA, van Kapel J, Schoester M, Sonneveld P (1992) Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype. Cancer Chemother Pharmacol 30:238–242CrossRefPubMedGoogle Scholar
  37. 37.
    Boesch D, Loor F (1994) Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents. Anticancer Drugs 5:229–238CrossRefPubMedGoogle Scholar
  38. 38.
    Michieli M, Damiani D, Michelutti A et al (1994) Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833. Haematologica 79:500–507PubMedGoogle Scholar
  39. 39.
    Zacherl J, Hamilton G, Thalhammer T et al (1994) Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH. Cancer Chemother Pharmacol 34:125–132CrossRefPubMedGoogle Scholar
  40. 40.
    Barrand MA, Rhodes T, Center MS, Twentyman P (1993) Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190 k membrane protein distinct from P-glycoprotein. Eur J Cancer 29A:408–415CrossRefPubMedGoogle Scholar
  41. 41.
    Van der Holt B, Lowenberg B, Burnett AK et al (2005) The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106:2646–2654CrossRefPubMedGoogle Scholar
  42. 42.
    Baer MR, George SL, Dodge RK et al (2002) Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100:1224–1232PubMedGoogle Scholar
  43. 43.
    Kolitz JE, George SL, Dodge RK et al (2004) Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 22:4290–4301CrossRefPubMedGoogle Scholar
  44. 44.
    Greenberg PL, Lee SJ, Advani R et al (2004) Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 22:1078–1086CrossRefPubMedGoogle Scholar
  45. 45.
    Fracasso PM, Brady MF, Moore DH et al (2001) Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 19:2975–2982PubMedGoogle Scholar
  46. 46.
    Zamora JM, Beck WT (1986) Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells. Biochem Pharmacol 35:4303–4310CrossRefPubMedGoogle Scholar
  47. 47.
    Wang RB, Kuo CL, Lien LL, Lien EJ (2003) Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 28:203–228CrossRefPubMedGoogle Scholar
  48. 48.
    Dhainaut A, Regnier G, Atassi G et al (1992) New triazine derivatives as potent modulators of multidrug resistance. J Med Chem 35:2481–2496CrossRefPubMedGoogle Scholar
  49. 49.
    Hill BT, van der Graaf WT, Hosking LK et al (1993) Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms in vitro. Int J Cancer 55:330–337CrossRefPubMedGoogle Scholar
  50. 50.
    Punt CJ, Voest EE, van Oosterom AT et al (1997) Phase 1B study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal cancer and renal cell cancer. Br. J. Cancer 76:1376–1381PubMedGoogle Scholar
  51. 51.
    Germann UA, Shlyakhter D, Mason VS (1997) Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8:125–140CrossRefPubMedGoogle Scholar
  52. 52.
    Germann UA, Ford PJ, Shlyakhter D, Mason VS, Harding MW (1997) Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 8:141–155CrossRefPubMedGoogle Scholar
  53. 53.
    Minderman H, O’Loughlin KL, Pendyala L, Baer MR (2004) VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 10:1826–1834CrossRefPubMedGoogle Scholar
  54. 54.
    Gandhi L, Harding MW, Neubauer M et al (2007) A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer 109:924–932CrossRefPubMedGoogle Scholar
  55. 55.
    Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595–4602PubMedGoogle Scholar
  56. 56.
    Myer MS, Joone G, Chasen MR, van Rensburg CE (1999) The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line. Oncol Rep 6:217–218PubMedGoogle Scholar
  57. 57.
    Martin C, Berridge G, Mistry P et al (2000) Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry 39:11901–11906CrossRefPubMedGoogle Scholar
  58. 58.
    De Bruin M, Miyake K, Litman T, Robey R, Bate SE (1999) Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 146: 117–126CrossRefPubMedGoogle Scholar
  59. 59.
    Maliepaard M, van Gastelen MA, Tohgo A et al (2001) Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 7:935–941PubMedGoogle Scholar
  60. 60.
    Elgie AW, Sargent JM, Williamson CJ, Lewandowicz GM, Taylor CG (1999) Comparison of P-glycoprotein expression and function with in vitro sensitivity to anthracyclines in AML. Adv Exp Med Biol 457: 29–33PubMedGoogle Scholar
  61. 61.
    Witherspoon SM, Emerson DL, Kerr BM et al (1996) Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res 2:7–12PubMedGoogle Scholar
  62. 62.
    den Ouden D, van den Heuvel M, Schoester M, van Rens G, Sonneveld P (1996) In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells. Leukemia 10: 1930–1936Google Scholar
  63. 63.
    Dal IL, Tuffley W, Callaghan R et al (1998) Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer 78:885–892Google Scholar
  64. 64.
    Roe M, Folkes A, Ashworth P et al (1999) Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett 9:595–600CrossRefPubMedGoogle Scholar
  65. 65.
    Mistry P, Stewart AJ, Dangerfield W et al (2001) In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61:749–758PubMedGoogle Scholar
  66. 66.
    Walker J, Martin C, Callaghan R (2004) Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Eur J Cancer 40: 594–605CrossRefPubMedGoogle Scholar
  67. 67.
    Martin C, Berridge G, Mistry P et al (1999) The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 128:403–411CrossRefPubMedGoogle Scholar
  68. 68.
    Martin C, Berridge G, Mistry P et al (2000) Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry 39:11901–11906CrossRefPubMedGoogle Scholar
  69. 69.
    Labrie P, Maddaford SP, Lacroix J et al (2006) In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity at CYP-450. Bioorg Med Chem 14:7972–7987CrossRefPubMedGoogle Scholar
  70. 70.
    Robey RW, Steadman K, Polgar O et al (2004) Pheophorbide A is a specific probe for ABCG2 function and inhibition. Cancer Res 64:1242–1246CrossRefPubMedGoogle Scholar
  71. 71.
    Pusztai L, Wagner P, Ibrahim N et al (2005) Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant advanced breast cancer. Cancer 104:682–691CrossRefPubMedGoogle Scholar
  72. 72.
    Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10:159–165PubMedGoogle Scholar
  73. 73.
    Nobili S, Landini I, Giglioni B, Mini E (2006) Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7:861–879CrossRefPubMedGoogle Scholar
  74. 74.
    Fox E, Bates SE (2007) Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 7:447–459CrossRefPubMedGoogle Scholar
  75. 75.
    Sato W, Fukazawa N, Suzuki T, Yusa K, Tsuruo T (1991) Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res 51:2420–2424PubMedGoogle Scholar
  76. 76.
    Dantzig AH, Shepard RL, Cao J et al (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56:4171–4179PubMedGoogle Scholar
  77. 77.
    Green LJ, Marder P, Slapak CA (2001) Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. Biochem Pharmacol 61:1393–1399CrossRefPubMedGoogle Scholar
  78. 78.
    Dantzig AH, Shepard RL, Law KL et al (1999) Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 290:854–862PubMedGoogle Scholar
  79. 79.
    Starling JJ, Shepard RL, Cao J et al (1997) Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv Enzyme Regul 37:335–347CrossRefPubMedGoogle Scholar
  80. 80.
    Lehne G, Morkrid L, den Boer M, Rugstad HE (2000) Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP). Int J Clin Pharmacol Ther 38:187–195PubMedGoogle Scholar
  81. 81.
    Shepard RL, Cao J, Starling JJ, Dantzig AH (2003) Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 103:121–125CrossRefPubMedGoogle Scholar
  82. 82.
    Bardelmeijer HA, Ouwehand M, Beijnen JH, Schellens JH, van Tellingen O (2004) Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs 22:219–229CrossRefPubMedGoogle Scholar
  83. 83.
    Callies S, de Alwis DP, Harris A et al (2003) A population pharmacokinetic model for paclitaxel in the presence of a novel Pgp modulator, Zosuquidar Trihydrochloride (LY335979). Br J Clin Pharmacol 56:46–56CrossRefPubMedGoogle Scholar
  84. 84.
    Rubin EH, de Alwis DP, Pouliquen I et al (2002) A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar. 3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res 8:3710–3717PubMedGoogle Scholar
  85. 85.
    Sandler A, Gordon M, De Alwis DP et al (2004) A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 10:3265–3272CrossRefPubMedGoogle Scholar
  86. 86.
    Fracasso PM, Goldstein LJ, de Alwis DP et al (2004) Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 10:7220–7228CrossRefPubMedGoogle Scholar
  87. 87.
    Gerrard G, Payne E, Baker RJ et al (2004) Clinical effect and P-glycoprotein inhibition in patients with acute myeloid leukaemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 89:782–790PubMedGoogle Scholar
  88. 88.
    Le LH, Moore MJ, Siu LL et al (2005) Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother Pharmacol 56:154–160CrossRefPubMedGoogle Scholar
  89. 89.
    Cripe LD, Li X, Litzow M et al (2006) A randomized, placebo-controlled, double blind trial of the MDR modulator, zosuquidar, during conventional induction and post-remission therapy for pts > 60 years of age with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): ECOG 3999. ASH Annu Meet Abstr 108:423Google Scholar
  90. 90.
    Hubesack M, Muller C, Hocherl P et al (2008) Effect of ABCB1 modulators elacridar and tariquidar on the distribution of pacltaxel in nude mice. J Cancer Res Clin Oncol 134:597–607CrossRefGoogle Scholar
  91. 91.
    Newman MJ, Roadarte JC, Benbatoul KD et al (2000) Discovery and characteri­sation of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 60:2964–2972PubMedGoogle Scholar
  92. 92.
    Guns ES, Bullock PL, Reimer ML et al (2001) Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes. Eur J Drug Metab Pharmacokinet 26:273–282PubMedGoogle Scholar
  93. 93.
    Deferme S, Van Gelder J, Augustijns P (2002) Inhibitory effect of fruit extracts on P-glycoprotein-related efflux carriers: an in-vitro screening. J Pharm Pharmacol 54:1213–1219CrossRefPubMedGoogle Scholar
  94. 94.
    Honda Y, Ushigome F, Koyabu N et al (2004) Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 143:856–864CrossRefPubMedGoogle Scholar
  95. 95.
    Limtrakul P, Khantamat O, Pintha K (2005) Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother 17:86–95PubMedGoogle Scholar
  96. 96.
    Chan KF, Zhao Y, Burkett BA et al (2006) Flavonoid dimmers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells. J Med Chem 49:6742–6759CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Biological Sciences, Faculty of Health and Medical SciencesUniversity of SurreyGuildfordUK

Personalised recommendations